Abstract:Spinocerebellar ataxia type 7 (SCA7) is a rare autosomal dominant neurodegenerative disorder characterized by progressive neuronal loss in the cerebellum, brainstem, and retina, leading to cerebellar ataxia and blindness as major symptoms. SCA7 is due to the expansion of a CAG triplet repeat that is translated into a polyglutamine tract in ATXN7. Larger SCA7 expansions are associated with earlier onset of symptoms and more severe and rapid disease progression. Here, we summarize the pathological and genetic aspects of SCA7, compile the current knowledge about ATXN7 functions, and then focus on recent advances in understanding the pathogenesis and in developing biomarkers and therapeutic strategies. ATXN7 is a bona fide subunit of the multiprotein SAGA complex, a transcriptional coactivator harboring chromatin remodeling activities, and plays a role in the differentiation of photoreceptors and Purkinje neurons, two highly vulnerable neuronal cell types in SCA7. Polyglutamine expansion in ATXN7 causes its misfolding and intranuclear accumulation, leading to changes in interactions with native partners and/or partners sequestration in insoluble nuclear inclusions. Studies of cellular and animal models of SCA7 have been crucial to unveil pathomechanistic aspects of the disease, including gene deregulation, mitochondrial and metabolic dysfunctions, cell and non-cell autonomous protein toxicity, loss of neuronal identity, and cell death mechanisms. However, a better understanding of the principal molecular mechanisms by which mutant ATXN7 elicits neurotoxicity, and how interconnected pathogenic cascades lead to neurodegeneration is needed for the development of effective therapies. At present, therapeutic strategies using nucleic acid-based molecules to silence mutant ATXN7 gene expression are under development for SCA7.

Molecular Mechanisms and Therapeutics for SCA17

Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis.

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion

Genetically Modified Rodent Models of SCA17

Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17.

Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

Recent Progress in the Molecular Genetics of Spinocerebellar Ataxias (Scas)

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets

Cerebellum-Enriched Protein Inpp5a Contributes To Selective Neuropathology In Mouse Model Of Spinocerebellar Ataxias Type 17

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice

Mutation Analysis of the TATA Box-Binding Protein (TBP) Gene in Chinese Han Patients with Spinocerebellar Ataxia

An insight into advances in the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3

The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias

Progress about Gene Research of Spinocerebellar Ataxia

The Clinical Features and Gene Mutation Analysis in a Pedigree of Spinocerebellar Ataxia Type 7

A patient with SCA17 featuring 41 CAG repeats presents with spastic paraplegia and involuntary movement

Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models